By PPN News Staff
The FDA approved pegfilgrastim-bmez (Ziextenzo, Sandoz), a new biosimilar to decrease the incidence of febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia.
Ziextenzo is the third biosimilar to pegfilgrastim (Neulasta, Amgen).
The FDA approval of pegfilgrastim-bmez was based on analytical, preclinical and clinical research, including data from a pivotal